UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 23.820

Sortiert nach

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

The lancet oncology, 2019-12, Vol.20 (12), p.1681-1690

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.74-89

2022

Link zum Volltext

Verfügbarkeit prüfen

Symptom experiences and health‐related quality of life among non‐small cell lung cancer patients participating in clinical trials

Journal of clinical nursing, 2019-06, Vol.28 (11-12), p.2111-2123

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Link zum Volltext

Verfügbarkeit prüfen

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.423-433

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Oncoimmunology, 2018-01, Vol.7 (1), p.e1375642-e1375642

2018

Link zum Volltext

Verfügbarkeit prüfen

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Scientific reports, 2021-10, Vol.11 (1), p.19596-19596, Article 19596

2021

Link zum Volltext

Verfügbarkeit prüfen

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Critical reviews in oncology/hematology, 2022-12, Vol.180, p.103847-103847, Article 103847

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

PloS one, 2020-04, Vol.15 (4), p.e0231546-e0231546

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

PloS one, 2019-11, Vol.14 (11), p.e0224379-e0224379

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

British journal of cancer, 2021-02, Vol.124 (4), p.713-720

2021

Link zum Volltext

Verfügbarkeit prüfen

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

BMC cancer, 2021-06, Vol.21 (1), p.1-731, Article 731

2021

Link zum Volltext

Verfügbarkeit prüfen

Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study

Cancer medicine (Malden, MA), 2024-04, Vol.13 (7), p.e7174-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center

PloS one, 2019-08, Vol.14 (8), p.e0221065-e0221065

2019

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer

Cancer letters, 2017-10, Vol.406, p.47-53

2017

Link zum Volltext

Verfügbarkeit prüfen

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107509-107509, Article 107509

2024

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib

Cancer letters, 2016-03, Vol.372 (1), p.75-81

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

Cancer imaging, 2023-10, Vol.23 (1), p.102-102, Article 102

2023

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Journal of clinical pharmacology, 2019-08, Vol.59 (8), p.1099-1109

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 23.820

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Korean Neurosurgical Society

KollektionPublisher site

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17.931)
Mit Volltextzugriff
(21.895)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Koreanisch
(22.412)
Englisch
(1.413)
Japanisch
(65)

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.432)
농학
(1.109)
Technology
(835)
Humans
(807)
Engineering
(689)
Materials Science
(669)
Materials Science, Multidisciplinary
(654)
Engineering, Multidisciplinary
(652)
Male
(593)
Life Sciences & Biomedicine
(573)
Female
(554)
Middle Aged
(496)
내과학
(418)
Adult
(409)
Aged
(408)
생물학
(242)
Helicobacter Pylori
(216)
약학
(212)
Prognosis
(206)
고분자공학
(165)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Symptom experiences and health‐related quality of life among non‐small cell lung cancer patients participating in clinical trials

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study

Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Aktive Filter

Suchergebnisse filtern